£90.30

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

Oncology

Price data last checked 153 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the usual price. Wait for it to drop, or tell us your number.

£90 today · usual range £0–£0 · best ever £67

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 578 days • 578 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 578 days • 5 price ranges

Days at Price

Current Price

Price Analysis

Most common range: £80-92 (193 days, 33.4%)

Price range: £67 - £128

Price levels: 5 price ranges over 578 days

Description

Lung cancer is the most common and most lethal malignancy world-wide, causing 1.4 million diseases every year. Half of non-small cell lung cancers (NSCLC) are diagnosed at such an advanced stage that a cure cannot be considered a realistic aim, and over 75% of cases selected for a curative treatment eventually relapse within five years. The 5-year overall survival rates are less than 20% for NSCLC patients. As a disease, NSCLC demands our maximum abilities as researchers, physicians, and care-givers, and a continuous updating of our knowledge. Conventional chemotherapy for advanced NSCLC does not provide a great long-term benefit in terms of survival. Accordingly, a different therapeutic approach has to be explored. The human epidermal growth factor family of surface receptors (HER) became a critical target to be investigated. The epidermal growth factor receptor (EGFR) is over-expressed in over 80% of non-small cell lung cancer. The presence of sensitising conformational mutations in the EGFR increases the efficacy of modern tyrosine kinase inhibitors against its inner portion (EGFR-TKI). The EGFR-TKIs greatly prolong disease-free survival of those patients harbouring sensitising EGFR mutations, and have been suggested as an essential tool in the therapeutic repertoire. This volume aims to serve as an updated compendium of biology and applications of anti-EGFR therapies, and offers a look at the future of anti-HER therapy in lung cancer. This volume exhaustively reviews and discusses: 1) the nature and significance of activating EGFR mutations, and those clinical and pathological phenomena related to HER alterations; 2) the most common laboratory methodologies to study EGFR, and the future of HER analysis; 3) the right time to analyse EGFR mutations and evolutionary changes in the HER; 4) EGFR-TKI application in unselected and selected NSCLC patients; 5) upcoming anti-HER therapies; 6) the eventual role of anti-HER therapies in early NSCLC; 7) mechanisms of acquired resistance to anti-HER therapies, and experimental and conventional strategies to bypass them; 8) the application of anti-HER therapies in other malignancies. This book is an indispensable handbook for all those specialists devoted to the diagnosis and management of lung cancer.

Product Specifications

Format: hardcover
ASIN: 1633210928
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 01 September 2014
Listed Since: 20 April 2014

Barcode

No barcode data available

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

This is the usual price. Wait for it to drop, or tell us your number.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews: 75 (Methods in Molecular Medicine, 75)

Lung Cancer and Personalized Medicine: Current Knowledge and Therapies: 893 (Advances in Experimental Medicine and Biology, 893)

Lung Cancer: Treatment and Research: 170

Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)

Springer - Lung Cancer: Treatment and Research: 170 Book

Lung Cancer (MD Anderson Cancer Care Series)

Lung Cancer: A Comprehensive Overview (Cancer Etiology, Diagnosis and Treatments)

Targeted Therapies for Lung Cancer (Current Cancer Research)

McGraw-Hill Lung Cancer: Standards of Care (Hematology/Oncology)

Lung Cancer Treatment (Cancer Etiology, Diagnosis and Treatments)

Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)

Advances in Clinical Science: 878 (Advances in Experimental Medicine and Biology, 878)

Lung Cancer Therapy Annual 7

Lung Cancer, Part II, An Issue of Clinics in Chest Medicine: Volume 41-2 (The Clinics: Internal Medicine, Volume 41-2)

Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management

Oxford Case Histories in Lung Cancer

Lung Cancer, An Issue of Clinics in Chest Medicine (Volume 32-4) (The Clinics: Internal Medicine, Volume 32-4)

Lung Cancer, An Issue of Hematology/Oncology Clinics (Volume 31-1) (The Clinics: Internal Medicine, Volume 31-1)

Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

Lung Cancer: Advances in Basic and Clinical Research: 72 (Cancer Treatment and Research, 72)

Lung Cancer: Advances in Basic and Clinical Research: 72 (Cancer Treatment and Research, 72)

Precision Molecular Pathology of Lung Cancer (Molecular Pathology Library)

Lung Cancer, Part I, An Issue of Clinics in Chest Medicine: Volume 41-1 (The Clinics: Internal Medicine, Volume 41-1)

New Therapeutic Strategies in Lung Cancers